A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic Melanoma
| Registry | NCT03123783 |
|---|---|
| Status | Completed |
| Phase | Phase 1 / Phase 2 |
| Study type | Interventional; non randomized, sequential, masking: none, treatment |
| Enrollment | 140 (Actual) |
| Sponsor | Apexigen America, Inc. (Industry); collaborators: Bristol-Myers Squibb |
| Conditions | Cancer, Non Small Cell Lung Cancer Metastatic, Metastatic Melanoma, Neoplasm of Lung, Melanoma |
| Interventions | APX005M, Nivolumab (Drug) |
| Dates | start 2017-07-10, primary completion 2020-11-16, completion 2020-11-16, first posted 2017-04-21, last updated 2023-12-26 |
| Locations | 23 sites in United States, Spain |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Cancer All trials for Non Small Cell Lung Cancer Metastatic All trials of APX005M All trials of Nivolumab
This study is a Phase 1-2 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M administered in combination with nivolumab to adult subjects with non-small cell lung cancer or metastatic melanoma. The Phase 1 portion is intended to establish the maximum tolerated dose and the recommended phase 2 dose of APX005M when administered in combination with nivolumab. The Phase 2 portion of the study will evaluate safety and efficacy of the combination.
APX005M-002 is an open-label Phase 1-2 study and comprises a dose-escalation portion (Phase 1) followed by a Phase 2 tumor specific portion.
Eligible subjects with non-small cell lung cancer or metastatic melanoma will receive intravenous APX005M in combination with nivolumab until disease progression, unacceptable toxicity or death, whichever occurs first.
Study objectives include:
* Determine the maximum tolerated dose and the recommended phase 2 dose of APX005M when given in combination with nivolumab
* Evaluate safety of the APX005M and nivolumab combination
* Evaluate the objective response rate, duration of response and median PFS by RECIST 1.1 in subjects with non-small cell lung cancer or metastatic melanoma receiving APX005M in combination with nivolumab
* Determine the PK of APX005M
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Phase 1b escalation 0.03 mg/kg | Experimental | Drug: APX005M; Drug: Nivolumab | Non-small cell lung cancer (NSCLC) or metastatic melanoma APX005M 0.03 mg/kg and nivolumab 360 mg every 3 weeks |
| Phase 1b escalation 0.1 mg/kg | Experimental | Drug: APX005M; Drug: Nivolumab | Non-small cell lung cancer (NSCLC) or metastatic melanoma APX005M 0.1 mg/kg and nivolumab 360 mg every 3 weeks |
| Phase 1b escalation 0.3 mg/kg | Experimental | Drug: APX005M; Drug: Nivolumab | Non-small cell lung cancer (NSCLC) or metastatic melanoma APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks |
| Phase 2 expansion Cohort 1 | Experimental | Drug: APX005M; Drug: Nivolumab | Immunotherapy naïve, metastatic or locally advanced NSCLC APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks |
| Phase 2 expansion Cohort 2 | Experimental | Drug: APX005M; Drug: Nivolumab | Metastatic melanoma progressing during treatment with anti-PD-1/PD-L1 therapy APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks |
| Phase 2 expansion Cohort 3 | Experimental | Drug: APX005M; Drug: Nivolumab | Metastatic or locally advanced NSCLC progressing during treatment with anti-PD-1/PD-L1: * Group A: best response of progressive disease or with stable disease < 16 weeks * Group B: tumor response or with stable disease ≥ 16 weeks |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Histologically or cytologically confirmed, immunotherapy naïve or PD-1/PD-L1 pre-treated, metastatic or locally advanced non-small cell lung cancer not amenable to curative treatment. Subjects may be treatment naive or could have received one prior platinum based chemotherapy for non-small cell lung cancer and subjects with a documented activating mutation (e.g., EGFR, ALK, ROS) must also have received the appropriate therapy and progressed * Histologically or cytologically confirmed unresectable or metastatic melanoma that progressed during treatment with an anti-PD-1/PD-L1 therapy and had confirmation of PD>=4 weeks later. Subjects with BRAF activating mutation could have also received a BRAF inhibitor and/or MEK inhibitor regimen prior to anti-PD-1/PD-L1 therapy. * Measurable disease by RECIST 1.1 * ECOG performance status of 0 or 1 * Adequate bone marrow, liver and kidney function * Negative pregnancy test for women of child bearing potential * Agreement to use effective methods of contraception per the protocol requirements Exclusion Criteria: * Previous exposure to any immunomodulatory agents (e.g., anti- CD40, anti-PD-1/PD-L1, anti-CTLA-4, IDO inhibitors) except PD-1/PD-L1 targeting agents in the subsets of patients that must have previous treatment with anti-PD-1/PD-L1 therapy * Second malignancy (solid or hematologic) within the past 3 years except locally curable cancers that have been apparently cured * Active, known, clinically serious infections within the 14 days prior to first dose of investigational product * Use of systemic corticosteroids or other systemic immunosuppressive drugs * Active, known or suspected autoimmune disease * History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis * History of interstitial lung disease * History of life-threatening toxicity related to prior anti-PD-1/PD-L1 treatment for subjects with metastatic melanoma or NSCLC.
| Milestone | DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b) | DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b) | DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b) | Cohort 1(Arm)/ inNSCLC (Phase 2) | Cohort 2(Arm)/ PD1-MM (Phase 2) - | Cohort 3A(Arm)/ PD1-NSCLC (Phase 2) | Cohort 3B(Arm)/ PD1-NSCLC (Phase 2) |
|---|---|---|---|---|---|---|---|
| Started | 3 | 4 | 3 | 0 | 0 | 0 | 0 |
| Participants in the safety population | 3 | 3 | 3 | 0 | 0 | 0 | 0 |
| Participants in the efficacy population | 3 | 3 | 3 | 0 | 0 | 0 | 0 |
| Completed | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 1 | 3 | 0 | 0 | 0 | 0 |
Time frame: Day 1 through 30 days (or 100 days for SAEs and AEs with potential immunologic etiology) after the last dose of study drug (up to 27 months)
| Arm | Deaths | Serious adverse events | Other adverse events |
|---|---|---|---|
| DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b Escalation) | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100.0%) |
| DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b Escalation) | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100.0%) |
| DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b Escalation) | 0/3 (0.0%) | 0/3 (0.0%) | 3/3 (100.0%) |
| Cohort 1(Arm)/ inNSCLC (Phase 2) - Includes Data From 1 Participant From DL3 | 18/53 (34.0%) | 25/53 (47.2%) | 52/53 (98.1%) |
| Cohort 2(Arm)/ PD1-MM (Phase 2) - Includes Data From 2 Participants From DL3 | 4/38 (10.5%) | 6/38 (15.8%) | 36/38 (94.7%) |
| Cohort 3A(Arm)/ PD1-NSCLC (Phase 2) | 4/14 (28.6%) | 6/14 (42.9%) | 14/14 (100.0%) |
| Cohort 3B(Arm)/ PD1-NSCLC (Phase 2) | 9/28 (32.1%) | 13/28 (46.4%) | 28/28 (100.0%) |
| Term | Organ system | DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b Escalation) | DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b Escalation) | DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b Escalation) | Cohort 1(Arm)/ inNSCLC (Phase 2) - Includes Data From 1 Participant From DL3 | Cohort 2(Arm)/ PD1-MM (Phase 2) - Includes Data From 2 Participants From DL3 | Cohort 3A(Arm)/ PD1-NSCLC (Phase 2) | Cohort 3B(Arm)/ PD1-NSCLC (Phase 2) |
|---|---|---|---|---|---|---|---|---|
| Acute coronary syndrome | Cardiac disorders | 0/3 | 0/3 | 0/3 | 2/53 | 0/38 | 0/14 | 0/28 |
| Acute myocardial infarction | Cardiac disorders | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Cardiac arrest | Cardiac disorders | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 1/14 | 0/28 |
| Cardio-respiratory arrest | Cardiac disorders | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Pericardial effusion | Cardiac disorders | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 1/14 | 0/28 |
| Constipation | Gastrointestinal disorders | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Gastritis | Gastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 0/14 | 1/28 |
| Intestinal obstruction | Gastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/53 | 1/38 | 0/14 | 0/28 |
| Pancreatitis | Gastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 0/14 | 1/28 |
| Pancreatitis acute | Gastrointestinal disorders | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Facial pain | General disorders | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| General physical health deterioration | General disorders | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 1/28 |
| Pain | General disorders | 0/3 | 0/3 | 0/3 | 0/53 | 1/38 | 0/14 | 0/28 |
| Pyrexia | General disorders | 0/3 | 1/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Cytokine release syndrome | Immune system disorders | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 0/14 | 2/28 |
| Appendicitis | Infections and infestations | 0/3 | 0/3 | 0/3 | 0/53 | 1/38 | 0/14 | 0/28 |
| Bacteraemia | Infections and infestations | 0/3 | 0/3 | 0/3 | 0/53 | 1/38 | 0/14 | 1/28 |
| Bronchitis | Infections and infestations | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 0/14 | 1/28 |
| Infuenza | Infections and infestations | 0/3 | 0/3 | 0/3 | 0/53 | 1/38 | 0/14 | 0/28 |
| Lung abscess | Infections and infestations | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Lung infection | Infections and infestations | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Pneumonia | Infections and infestations | 0/3 | 1/3 | 0/3 | 4/53 | 0/38 | 2/14 | 2/28 |
| Sepsis | Infections and infestations | 1/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 1/28 |
| Streptococcal bacteraemia | Infections and infestations | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Fall | Injury, poisoning and procedural complications | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 0/14 | 1/28 |
| Femur fracture | Injury, poisoning and procedural complications | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 1/28 |
| Hip fracture | Injury, poisoning and procedural complications | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Radius fracture | Injury, poisoning and procedural complications | 0/3 | 0/3 | 0/3 | 0/53 | 1/38 | 0/14 | 0/28 |
| Toxicity to various agents | Injury, poisoning and procedural complications | 0/3 | 0/3 | 0/3 | 0/53 | 1/38 | 0/14 | 0/28 |
| Blood bilirubin increased | Investigations | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Weight decreased | Investigations | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Diabetic ketoacidosis | Metabolism and nutrition disorders | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Hypercalcaemia | Metabolism and nutrition disorders | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 0/14 | 1/28 |
| Hyperglycaemia | Metabolism and nutrition disorders | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 0/14 | 1/28 |
| Arthralgia | Musculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 0/14 | 1/28 |
| Back pain | Musculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Myositis | Musculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 0/14 | 1/28 |
| Bone neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Cancer pain | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 1/14 | 1/28 |
| Brain oedema | Nervous system disorders | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 1/14 | 0/28 |
| Cerebrovascular accident | Nervous system disorders | 0/3 | 0/3 | 0/3 | 2/53 | 0/38 | 0/14 | 0/28 |
| Encephalitis autoimmune | Nervous system disorders | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 1/14 | 0/28 |
| Seizure | Nervous system disorders | 0/3 | 0/3 | 0/3 | 2/53 | 0/38 | 0/14 | 0/28 |
| Syncope | Nervous system disorders | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Confusional state | Psychiatric disorders | 0/3 | 0/3 | 0/3 | 1/53 | 1/38 | 0/14 | 0/28 |
| Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 2/53 | 0/38 | 1/14 | 0/28 |
| Chronic respiratory failure | Respiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 2/53 | 0/38 | 1/14 | 2/28 |
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 2/53 | 0/38 | 0/14 | 0/28 |
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Pulmonary artery thrombosis | Respiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 3/53 | 0/38 | 1/14 | 2/28 |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 0/28 |
| Deep vein thrombosis | Vascular disorders | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 1/14 | 0/28 |
| Optic ischaemic neuropathy | Eye disorders | 0/3 | 1/3 | 0/3 | 0/53 | 0/38 | 0/14 | 0/28 |
| Acute kidney injury | Renal and urinary disorders | 0/3 | 1/3 | 0/3 | 0/53 | 0/38 | 0/14 | 0/28 |
| Colitis | Gastrointestinal disorders | 0/3 | 0/3 | 0/3 | 2/53 | 0/38 | 0/14 | 0/28 |
| Term | Organ system | DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b Escalation) | DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b Escalation) | DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b Escalation) | Cohort 1(Arm)/ inNSCLC (Phase 2) - Includes Data From 1 Participant From DL3 | Cohort 2(Arm)/ PD1-MM (Phase 2) - Includes Data From 2 Participants From DL3 | Cohort 3A(Arm)/ PD1-NSCLC (Phase 2) | Cohort 3B(Arm)/ PD1-NSCLC (Phase 2) |
|---|---|---|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | 0/3 | 2/3 | 0/3 | 13/53 | 4/38 | 0/14 | 6/28 |
| Palpitations | Cardiac disorders | 0/3 | 0/3 | 0/3 | 1/53 | 2/38 | 0/14 | 0/28 |
| Sinus tachycardia | Cardiac disorders | 0/3 | 0/3 | 0/3 | 3/53 | 1/38 | 0/14 | 1/28 |
| Tachycardia | Cardiac disorders | 0/3 | 1/3 | 1/3 | 7/53 | 2/38 | 1/14 | 2/28 |
| Hyperthyroidism | Endocrine disorders | 0/3 | 0/3 | 0/3 | 4/53 | 1/38 | 0/14 | 1/28 |
| Hypothyroidism | Endocrine disorders | 1/3 | 0/3 | 1/3 | 5/53 | 2/38 | 1/14 | 0/28 |
| Vision blurred | Eye disorders | 0/3 | 0/3 | 0/3 | 2/53 | 1/38 | 1/14 | 0/28 |
| Abdominal pain | Gastrointestinal disorders | 0/3 | 1/3 | 0/3 | 3/53 | 2/38 | 2/14 | 0/28 |
| Abdominal pain upper | Gastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/53 | 1/38 | 3/14 | 1/28 |
| Constipation | Gastrointestinal disorders | 1/3 | 0/3 | 1/3 | 10/53 | 5/38 | 3/14 | 0/28 |
| Diarrhoea | Gastrointestinal disorders | 0/3 | 1/3 | 2/3 | 12/53 | 6/38 | 2/14 | 2/28 |
| Dry mouth | Gastrointestinal disorders | 0/3 | 0/3 | 0/3 | 6/53 | 2/38 | 2/14 | 1/28 |
| Dyspepsia | Gastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/53 | 2/38 | 0/14 | 0/28 |
| Dysphagia | Gastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/53 | 1/38 | 0/14 | 2/28 |
| Nausea | Gastrointestinal disorders | 1/3 | 1/3 | 3/3 | 24/53 | 18/38 | 7/14 | 8/28 |
| Odynophagia | Gastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 0/14 | 2/28 |
| Stomatitis | Gastrointestinal disorders | 0/3 | 0/3 | 0/3 | 4/53 | 0/38 | 0/14 | 0/28 |
| Vomiting | Gastrointestinal disorders | 1/3 | 2/3 | 3/3 | 18/53 | 10/38 | 2/14 | 5/28 |
| Asthenia | General disorders | 0/3 | 0/3 | 0/3 | 7/53 | 6/38 | 4/14 | 12/28 |
| Chest discomfort | General disorders | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 2/14 | 0/28 |
| Chest pain | General disorders | 0/3 | 0/3 | 0/3 | 2/53 | 1/38 | 0/14 | 5/28 |
| Chills | General disorders | 0/3 | 2/3 | 3/3 | 30/53 | 19/38 | 5/14 | 13/28 |
| Fatigue | General disorders | 3/3 | 2/3 | 0/3 | 18/53 | 15/38 | 5/14 | 4/28 |
| Malaise | General disorders | 0/3 | 0/3 | 1/3 | 2/53 | 4/38 | 3/14 | 0/28 |
| Non-cardiac chest pain | General disorders | 0/3 | 0/3 | 0/3 | 5/53 | 0/38 | 0/14 | 0/28 |
| Oedema peripheral | General disorders | 0/3 | 2/3 | 0/3 | 4/53 | 3/38 | 3/14 | 2/28 |
| Pain | General disorders | 1/3 | 1/3 | 0/3 | 5/53 | 1/38 | 0/14 | 1/28 |
| Pyrexia | General disorders | 0/3 | 2/3 | 2/3 | 28/53 | 26/38 | 7/14 | 12/28 |
| Cytokine release syndrome | Immune system disorders | 0/3 | 1/3 | 0/3 | 3/53 | 0/38 | 0/14 | 1/28 |
| Nasopharyngitis | Infections and infestations | 0/3 | 0/3 | 0/3 | 3/53 | 1/38 | 0/14 | 2/28 |
| Pneumonia | Infections and infestations | 0/3 | 0/3 | 0/3 | 6/53 | 0/38 | 0/14 | 0/28 |
| Respiratory tract infection | Infections and infestations | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 4/28 |
| Sinusitis | Infections and infestations | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 2/28 |
| Upper respiratory tract infection | Infections and infestations | 0/3 | 0/3 | 0/3 | 2/53 | 4/38 | 2/14 | 0/28 |
| Urinary tract infection | Infections and infestations | 0/3 | 0/3 | 0/3 | 2/53 | 2/38 | 0/14 | 0/28 |
| Fall | Injury, poisoning and procedural complications | 0/3 | 0/3 | 0/3 | 4/53 | 0/38 | 0/14 | 0/28 |
| Infusion related reaction | Injury, poisoning and procedural complications | 0/3 | 0/3 | 0/3 | 5/53 | 3/38 | 2/14 | 3/28 |
| Alanine aminotransferase increased | Investigations | 0/3 | 1/3 | 0/3 | 11/53 | 11/38 | 4/14 | 8/28 |
| Blood alkaline phosphatase | Investigations | 0/3 | 0/3 | 0/3 | 0/53 | 0/38 | 2/14 | 0/28 |
| Blood alkaline phosphatase increased | Investigations | 0/3 | 1/3 | 0/3 | 9/53 | 7/38 | 1/14 | 3/28 |
| Blood bilirubin increased | Investigations | 1/3 | 0/3 | 1/3 | 3/53 | 3/38 | 0/14 | 1/28 |
| Blood creatinine increased | Investigations | 0/3 | 0/3 | 0/3 | 5/53 | 1/38 | 1/14 | 1/28 |
| Blood lactate dehydrogenase increased | Investigations | 0/3 | 0/3 | 0/3 | 0/53 | 3/38 | 0/14 | 1/28 |
| Gamma-glutamyltransferase increased | Investigations | 0/3 | 0/3 | 0/3 | 8/53 | 7/38 | 4/14 | 5/28 |
| Haemoglobin decreased | Investigations | 0/3 | 0/3 | 0/3 | 1/53 | 1/38 | 0/14 | 3/28 |
| Lipase increased | Investigations | 0/3 | 0/3 | 0/3 | 5/53 | 1/38 | 0/14 | 0/28 |
| Platelet count decreased | Investigations | 0/3 | 0/3 | 0/3 | 4/53 | 1/38 | 0/14 | 0/28 |
| Weight decreased | Investigations | 0/3 | 1/3 | 0/3 | 14/53 | 0/38 | 1/14 | 3/28 |
| Decreased appetite | Metabolism and nutrition disorders | 1/3 | 2/3 | 1/3 | 14/53 | 4/38 | 4/14 | 7/28 |
| Dehydration | Metabolism and nutrition disorders | 0/3 | 1/3 | 0/3 | 5/53 | 0/38 | 0/14 | 1/28 |
| Hypercalcaemia | Metabolism and nutrition disorders | 0/3 | 0/3 | 0/3 | 1/53 | 0/38 | 0/14 | 2/28 |
| Hyperglycaemia | Metabolism and nutrition disorders | 0/3 | 1/3 | 0/3 | 4/53 | 1/38 | 0/14 | 0/28 |
| Hypokalaemia | Metabolism and nutrition disorders | 0/3 | 0/3 | 0/3 | 4/53 | 0/38 | 0/14 | 2/28 |
| Hypomagnesaemia | Metabolism and nutrition disorders | 0/3 | 0/3 | 0/3 | 3/53 | 0/38 | 0/14 | 1/28 |
| Hyponatraemia | Metabolism and nutrition disorders | 1/3 | 0/3 | 0/3 | 4/53 | 1/38 | 0/14 | 1/28 |
| Arthralgia | Musculoskeletal and connective tissue disorders | 1/3 | 1/3 | 1/3 | 12/53 | 6/38 | 3/14 | 5/28 |
| Back pain | Musculoskeletal and connective tissue disorders | 1/3 | 1/3 | 0/3 | 8/53 | 4/38 | 1/14 | 2/28 |
| Bone pain | Musculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/3 | 3/53 | 0/38 | 0/14 | 1/28 |
| Flank pain | Musculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/3 | 3/53 | 0/38 | 0/14 | 1/28 |
| Muscular weakness | Musculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/3 | 4/53 | 0/38 | 0/14 | 0/28 |
95 more terms not shown.
Limitations and caveats: In the AE section, DL3 participant data had no DLTs; AE data collected from DL3 was also added to Phase 2.
| Facility | City | Country | Status |
|---|---|---|---|
| University of Arizona Cancer Center | Tucson, Arizona | United States | |
| City of Hope | Duarte, California | United States | |
| Yale University | New Haven, Connecticut | United States | |
| Hem-Onc Associates of the Treasure Coast | Port Saint Lucie, Florida | United States | |
| University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) | Baltimore, Maryland | United States | |
| Nebraska Cancer Specialists | Omaha, Nebraska | United States | |
| University of Nebraska Medical Center | Omaha, Nebraska | United States | |
| SUNY Upstate Medical Hospital | Syracuse, New York | United States | |
| University Hospitals Seidman Cancer Center | Cleveland, Ohio | United States | |
| Abramson Cancer Center of The University of Pennsylvania | Philadelphia, Pennsylvania | United States | |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania | United States | |
| Fox Chase Center | Rockledge, Pennsylvania | United States | |
| Tennessee Oncology | Nashville, Tennessee | United States | |
| Hospital Quirón Dexeus | Barcelona | Spain | |
| H. Vall d'Hebron | Barcelona | Spain | |
| H. Clinic i Provincial | Barcelona | Spain | |
| H. Insular de Gran Canaria | Las Palmas de Gran Canaria | Spain | |
| H. Lucus Augusti | Lugo | Spain | |
| H. Doce de Octubre | Madrid | Spain | |
| H. HM Sanchinnarro | Madrid | Spain | |
| H. de Málaga | Málaga | Spain | |
| H. La Fe | Valencia | Spain | |
| H. General de Valencia | Valencia de Alcántara | Spain |